315 results on '"van Werkhoven E"'
Search Results
2. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
3. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
4. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome
5. Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial
6. Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database
7. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
8. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment)
9. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
10. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group
11. The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes
12. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
13. Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube
14. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer:the randomized phase III NeoTN trial
15. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
16. Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design
17. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
18. Long-Term Outcomes of More Than a Decade Treating Patients with Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
19. The performance of model-based versus rule-based phase I clinical trials in oncology: A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years
20. Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period
21. P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
22. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours:a multicentre retrospective observational cohort study
23. Sex differences in patients with gastrointestinal stromal tumours:do they exist and does it affect survival?
24. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
25. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
26. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
27. Comparative study of brachytherapy vs. radical cystectomy for cT1-2 muscle-invasive bladder cancer
28. 1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
29. OC-0103 Comparative study of brachytherapy vs. radical cystectomy for cT1-2 muscle-invasive bladder cancer
30. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
31. Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
32. Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study
33. High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases
34. OC-0692: Phase 1 study of olaparib as radiosensitizer for locally advanced non-small cell lung cancer
35. Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial
36. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer
37. Minimally Invasive Complete Response Assessment of the breast after neoadjuvant systemic therapy (MICRA trial): Interim analysis of a multicenter observational cohort study
38. 594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients
39. The influence of hospital and surgeon volume on mortality and complications after radical cystectomy
40. Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment)
41. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
42. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
43. Personalised reimbursement : a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
44. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
45. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
46. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
47. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
48. 4LBA LBA Mini Oral - Young boost randomized phase III trial of high vs low boost radiation in young breast cancer patients: 10-year results.
49. P2.04-83 Long-Term Follow-Up Compassionate Use Program Nivolumab in NSCLC
50. Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.